HYBIO issued a profit warning, with a net profit attributable to the parent company of 142 million to 162 million yuan in the first half of the year, turning a loss into a profit year-on-year
I'm LongbridgeAI, I can summarize articles.HYBIO expects the net profit attributable to the parent company in the first half of 2025 to be between 142 million yuan and 162 million yuan, turning a profit compared to the same period last year. The company's main source of operating revenue comes from international business, benefiting from factors such as the growth in global market demand, the approval for the sale of liraglutide injection, an increase in raw material drug exports, and strict cost control, which have driven the overall profitability improvement
According to the Zhitong Finance APP, HYBIO (300199.SZ) released its semi-annual performance forecast for 2025, expecting a net profit attributable to shareholders of the listed company to be between 142 million yuan and 162 million yuan in the first half of the year, turning from a loss to a profit year-on-year.
During the reporting period, the company's main source of operating revenue came from international business. Benefiting from the continuous growth of global market demand, the approval certificate obtained for liraglutide injection submitted to the U.S. Food and Drug Administration on December 23, 2024, the continuous increase in raw material drug exports, the market competitiveness of the company's products, and strict cost control, the operating profit margin of international business was relatively high, further driving the overall profitability of the company